BR9809493A - In vivo modification of guar galactomannans by expression of udp-galactose epimerase antisense arn - Google Patents

In vivo modification of guar galactomannans by expression of udp-galactose epimerase antisense arn

Info

Publication number
BR9809493A
BR9809493A BR9809493-9A BR9809493A BR9809493A BR 9809493 A BR9809493 A BR 9809493A BR 9809493 A BR9809493 A BR 9809493A BR 9809493 A BR9809493 A BR 9809493A
Authority
BR
Brazil
Prior art keywords
galactose
mannose
udp
expression
vivo modification
Prior art date
Application number
BR9809493-9A
Other languages
Portuguese (pt)
Inventor
Morten Jorsboe
Janne Brunstedt
Steen Guldager Petersen
Original Assignee
Danisco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco filed Critical Danisco
Publication of BR9809493A publication Critical patent/BR9809493A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Resumo da Patente de Invenção para <B>''MODIFICAçãO IN VIVO DE GALACTOMANANAS EM GUAR POR EXPRESSãO DE ARN DE ANTI-SENTIDO DE UDP-GALACTOSE EPIMERASE''<D> é descrito um processo de modificação in vivo. O processo afeta a razão manose para galactose de um organismo (ou parte do mesmo) capaz de produzir um composto contendo manose / galactose ou de um composto contendo manose / galactose do mesmo. O processo de modificação in vivo compreende a expressão de uma seq³ência de nucleotídeos que tem um efeito sobre: (a) a razão de manose para galactose de componentes de manose e de galactose de um composto contendo manose / galactose; e/ou (b) a razão manose para galactose de precursores de manose e de galactose para um composto contendo manose / galactose; e sendo que a seq³ência de nucleotídeos é de anti-sentido com relação a pelo menos uma parte do gene para uma enzima UDP-galactose epimerase.Summary of the Patent for <B> '' IN VIVO MODIFICATION OF GALACTOMANANES IN GUAR BY EXPRESSION OF UDP-GALACTOSE EPIMERASE ANTI-SENSE RNA '' <D> describes an in vivo modification process. The process affects the mannose to galactose ratio of an organism (or part of it) capable of producing a compound containing mannose / galactose or a compound containing mannose / galactose therefrom. The in vivo modification process comprises the expression of a nucleotide sequence that has an effect on: (a) the ratio of mannose to galactose of mannose components and galactose of a compound containing mannose / galactose; and / or (b) the mannose to galactose ratio of mannose precursors and galactose to a compound containing mannose / galactose; and the nucleotide sequence is antisense with respect to at least part of the gene for a UDP-galactose epimerase enzyme.

BR9809493-9A 1997-05-28 1998-05-27 In vivo modification of guar galactomannans by expression of udp-galactose epimerase antisense arn BR9809493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9710990.4A GB9710990D0 (en) 1997-05-28 1997-05-28 Modification process
PCT/IB1998/000891 WO1998054335A1 (en) 1997-05-28 1998-05-27 In vivo modification of galactomannans in guar by expression of udp-galactose epimerase antisense rna

Publications (1)

Publication Number Publication Date
BR9809493A true BR9809493A (en) 2000-06-20

Family

ID=10813167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809493-9A BR9809493A (en) 1997-05-28 1998-05-27 In vivo modification of guar galactomannans by expression of udp-galactose epimerase antisense arn

Country Status (10)

Country Link
EP (1) EP0983369A1 (en)
JP (1) JP2002500515A (en)
KR (1) KR20010012962A (en)
CN (1) CN1264428A (en)
AU (1) AU733483B2 (en)
BR (1) BR9809493A (en)
CA (1) CA2291449A1 (en)
GB (2) GB9710990D0 (en)
NZ (1) NZ500951A (en)
WO (1) WO1998054335A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710990D0 (en) * 1997-05-28 1997-07-23 Danisco Modification process
ITPD980169A1 (en) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl AMIDES OF HYALURONIC ACID AND ITS DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
WO2000047748A2 (en) * 1999-02-10 2000-08-17 E.I. Du Pont De Nemours And Company Udp-glucose modifiers
US6992236B1 (en) 1999-02-10 2006-01-31 E. I. Du Pont De Nemours And Company Plant UDP-glucose epimerases
GB9914210D0 (en) 1999-06-17 1999-08-18 Danisco Promoter
AU2003290793A1 (en) 2002-11-14 2004-06-15 Pioneer Hi-Bred International, Inc. Genes for galactomannan production in plants and methods of use
ITPD20050056A1 (en) 2005-03-02 2006-09-03 Fidia Farmaceutici AMIDID DERIVATIVES OF HYALURONIC ACID IN OSTEOARTROSI
US7585818B2 (en) 2005-05-10 2009-09-08 Halliburton Energy Services, Inc. Nonnatural galactomannans and methods of use
EP2084264A1 (en) 2007-03-09 2009-08-05 Corning Incorporated Three dimensional gum matrices for cell culture, manufacturing methods and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK198089D0 (en) * 1989-04-24 1989-04-24 Danske Spritfabrikker DNA MATERIALS AND USE THEREOF
GB9524752D0 (en) * 1995-12-04 1996-02-07 Danisco Modification process
GB9710990D0 (en) * 1997-05-28 1997-07-23 Danisco Modification process

Also Published As

Publication number Publication date
JP2002500515A (en) 2002-01-08
GB9927197D0 (en) 2000-01-12
AU733483B2 (en) 2001-05-17
EP0983369A1 (en) 2000-03-08
NZ500951A (en) 2001-09-28
GB2342920B (en) 2001-08-15
GB9710990D0 (en) 1997-07-23
WO1998054335A1 (en) 1998-12-03
GB2342920A (en) 2000-04-26
KR20010012962A (en) 2001-02-26
CA2291449A1 (en) 1998-12-03
CN1264428A (en) 2000-08-23
AU7446398A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
IL152959A0 (en) Immunostimulatory oligodeoxynucleotides
BR9809493A (en) In vivo modification of guar galactomannans by expression of udp-galactose epimerase antisense arn
EP1182206A3 (en) Stabilized oligonucleotids and the use thereof
AU7621600A (en) Human rnase h and oligonucleotide compositions thereof
AU6589094A (en) 7-deazapurine modified oligonucleotides
AU5121399A (en) Rna targeted 2&#39;-modified oligonucleotides that are conformationally preorganized
EP0977767A4 (en) Aminooxy-modified oligonucleotides
PL328639A1 (en) Synthesis of p5&#39; phosphoamidane oligonucleotides n3&#39;
HK1154590A1 (en) Bicyclonucleoside oligonucleotide analogue
ATE196912T1 (en) PROPARGYLETHOXYAMINO NUCLEOTIDES
BR9808963A (en) Taqman tm-pcr for the detection of strains of e. pathogenic coli
BR9911491A (en) Process of treatment of a metallic surface to increase the resistance against corrosion, and, use of a treatment solution
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
DE69920247D1 (en) CHANGE IN DNA METHYL TRANSFERASE BY COMBINATION THERAPY
BR9803727A (en) Biostable water-based paints and process for their preparations.
BR0108771A (en) Processes for the preparation of a phosphorothioate triester, and unprotected oligonucleotide, oligonucleotide phosphorothioate, or mixed oligonucleotide / oligonucleotide phosphorothioate
EP0414607A3 (en) Anti-sense nucleotide sequence, anti rna against alpha tnf messenger rna, process for the preparation thereof, medical use thereof and its inclusion in pharmaceutical preparations
CA2070664A1 (en) Antisense oligonucleotide inhibition of papillomavirus
BR9915646A (en) Intermediates, process for the preparation of macrolide antibiotic agent from them
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
DESCHÊNES et al. Nucleotides-1 to-4 of hepatitis delta ribozyme substrate increase the specificity of ribozyme cleavage
BR9807563A (en) Composition useful in gene therapy comprising particles of complex cationic transfection agent (s) stabilized nucleic acids, and process for preparing the same.
Ghangas et al. Specific hydrolysis of the cohesive ends of bacteriophage lambda DNA by three single strand-specific nucleases.
BR0001906A (en) Process for the fermentative preparation of l-amino acids using corineform bacteria
BR0002493A (en) Process for the preparation of l-amino acids by fermentation and nucleotide sequences encoding the accda gene

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.